AOD-9604 vs HGH fragment 176-191: the difference explained

Research context (RUO): AOD-9604 and HGH fragment 176-191 are synthetic fragments of the C-terminal part of human growth hormone. At Peplife, both peptides are supplied exclusively for in-vitro laboratory research (Research Use Only) and are not intended for human or animal use.

AOD-9604 vs HGH fragment 176-191: the difference explained

The comparison AOD-9604 vs HGH fragment 176-191 often causes confusion, because the two peptides are credited with the same properties in virtually every table. That is no coincidence: AOD-9604 is literally the same fragment, with one amino acid stuck on the front. Yet that small difference is the reason one of them went through a full clinical development programme and the other never got beyond preclinical work. This pillar sets chemistry, research history and practical differences side by side, purely from a research perspective.

The core: the same fragment, one extra amino acid

Human growth hormone is a protein of 191 amino acids. Research from the nineteen-seventies and eighties showed that the fat-breakdown properties of the hormone reside largely in the tail section, residues 176 to 191. Producing that section on its own yielded HGH fragment 176-191, also known as the lipolytic domain. AOD-9604 is that same fragment with a tyrosine at the N-terminus: designated Tyr-hGH(177-191) in the literature. Sixteen amino acids against seventeen, otherwise identical.

Why that tyrosine was added

The addition was not a cosmetic move. Tyrosine makes the molecule suitable for radioiodination, allowing researchers to label the peptide and track it in tissue: a prerequisite for serious pharmacokinetic research. It also improved the stability of the molecule, which mattered for a candidate being developed as a tablet. The developers, affiliated with Monash University in Australia, named the substance AOD-9604, where AOD stands for anti-obesity drug and 9604 was the internal candidate number.

Lipolysis without the growth axis: what the animal studies showed

The reason this fragment became interesting is that it appears to separate the fat-metabolism effects of growth hormone from the growth-promoting effects. Ng and colleagues studied the fragment in rodent models in 2000, and Heffernan and colleagues did so in 2001. In both studies the fragment increased fat breakdown and inhibited fat build-up, without IGF-1 levels or insulin sensitivity shifting along with it. With intact growth hormone, the latter does happen. For research into fat metabolism, that separation principle is the whole point of this class of peptides.

The two fragments side by side

Clinical development: where the paths diverge

This is where the real difference between the two substances lies. AOD-9604 was developed further as a weight-loss agent and reached phase 2 in human studies. The outcome was disappointing: the agent did not meet the set endpoints compared with placebo, after which development as a medicine was halted. HGH fragment 176-191 never went down that route and rests almost entirely on preclinical work. Anyone placing the research dossiers of both substances side by side is therefore not comparing two molecules but two development histories — with the best-researched of the two delivering precisely the negative outcome.

What this means for the choice within a research model

For in-vitro work on adipocytes the tyrosine makes little difference: the lipolytic domain is the same in both cases and the effects measured in cell models therefore run parallel. For work in which the peptide has to be tracked or quantified in tissue, AOD-9604 is the more practical molecule, precisely because it was designed for that. The same applies to stability research. Anyone wanting to study purely the native fragment as it arises from growth hormone ends up with 176-191.

Doping rules and regulatory status

Neither substance is approved as a medicine by the EMA, NVWA or FDA. Both fall under the category of growth factors and related substances in the anti-doping code, which is relevant to anyone working with this class in a sports-related context. The article on peptides and doping rules describes how that classification works.

Both fragments in laboratory research: handling and dissolving

Both are supplied as freeze-dried powder and in that form are stable for long periods at minus twenty degrees Celsius. They are short peptides without disulfide bridges, which makes them relatively robust, but after reconstitution with bacteriostatic water the solution should be kept refrigerated and dark, and repeated freeze-thaw cycles are undesirable. The reconstitution guide sets out the calculation steps and the practicalities of preparation and storage.

Quality & purity

Two peptides that differ by just one amino acid cannot be told apart by eye: only mass spectrometry and HPLC show which of the two is actually in the vial. Every relevant batch is independently HPLC-tested by an external laboratory and the certificate of analysis is publicly verifiable per batch, so the research material demonstrably matches the specified peptide. In the article why we rejected a batch you can read how that process works in practice.

Frequently asked questions about AOD-9604 and HGH fragment 176-191

Are AOD-9604 and HGH fragment 176-191 the same?
Almost. AOD-9604 is the same C-terminal fragment with an extra tyrosine at the N-terminus, formally Tyr-hGH(177-191).

Why was that tyrosine added?
To make the molecule labelable for radioiodination and to improve its stability, both prerequisites for pharmacokinetic research.

Do these fragments raise IGF-1?
In the published rodent studies IGF-1 levels did not shift along with it, in contrast to intact growth hormone. That separation principle is precisely why these fragments are studied.

What happened to the clinical development of AOD-9604?
The substance reached phase 2 in human studies and did not meet the set endpoints compared with placebo, after which development as a weight-loss agent was halted.

Which of the two suits which research?
For cell work on adipose tissue the two run level. For tracing, quantification and stability work AOD-9604 is the more practical molecule; for research into the native fragment, 176-191.

Read more & research at Peplife

• Research AOD-9604 at Peplife
• HGH fragment 176-191 research at Peplife
• Research Frag 17-23 at Peplife
• View all metabolism peptides
• AOD-9604: research into the lipolytic domain
• HGH fragment 176-191: the research dossier
• Frag 17-23: research into the shorter fragment
• Lipotropic substances: research and context

Sources: Ng et al., Metabolic studies of a synthetic lipolytic domain (AOD9604), Horm Res 2000 · Heffernan et al., Effects of GH and AOD9604 on lipid metabolism, Endocrinology 2001 · PubChem: AOD-9604 (CID 71300630) · Ng et al., Am J Physiol 1978 — C-terminal growth hormone fragments

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.